Lead optimisation of dehydroemetine for repositioned use in malaria

Priyanka Panwar¹, Kepa K. Burusco², Muna Abubaker¹, Holly Matthews³, Andrey Gutnov⁴, Elena Fernández-Álvaro⁵, Richard A. Bryce², James Wilkinson¹, Niroshini Nirmalan¹*

¹Environment and Life Sciences, University of Salford, Greater Manchester, M5 4WT, UK.
²Division of Pharmacy and Optometry, School of Health Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Oxford Road, Manchester M13 9PL, UK.
³Keele University, Staffordshire, ST5 5BG, UK.
⁴Chiroblock GMBH, Andresenstrasse 1a, 06766 Wolfen, Germany.
⁵GlaxoSmithKline, Diseases of the Developing World Medicines Development Campus, Severo Ochoa, 2. Tres Cantos, 28760, Spain.

*Niroshini Nirmalan

E-mail: nj.nirmalan@salford.ac.uk

Keywords: malaria, antimalarial drug interactions, SYBR Green flow-cytometry, emetine, dehydroemetine, drug discovery, repositioning
Abstract:

Drug repositioning offers an effective alternative to de novo drug design to tackle the urgent need for novel anti-malarial treatments. The anti-amoebic compound, emetine dihydrochloride, has been identified as a potent in-vitro inhibitor of the multi-drug resistant strain K1 of *Plasmodium falciparum* (IC$_{50}$: 47 nM ± 2.1 nM). Dehydroemetine, a synthetic analogue of emetine dihydrochloride has been reported to have less cardiotoxic effects than emetine. The structures of two diastereomers of dehydroemetine were modelled on the published emetine binding site on cryo-EM structure 3J7A (Pf 80S ribosome in complex with emetine) and it was found that (−)-R,S-dehydroemetine mimicked the bound pose of emetine more closely than (−)-S,S-dehydroisoemetine. (−)-R,S-dehydroemetine (IC$_{50}$ 71.03 ± 6.1 nM) was also found to be highly potent against the multi-drug resistant K1 strain of *P. falciparum* in comparison with (−)-S,S-dehydroisoemetine (IC$_{50}$ 2.07 ± 0.26 µM), which loses its potency due to the change of configuration at C-1´. In addition to its effect on the asexual erythrocytic stages of *P. falciparum*, the compounds exhibited gametocidal properties with no cross-resistance against any of the multi-drug resistant strains tested. Drug interaction studies showed (−)-R,S-dehydroemetine to have synergistic antimalarial activity with atovaquone and proguanil. Emetine dihydrochloride, and (−)-R,S-dehydroemetine failed to show any inhibition of the hERG potassium channel and displayed activity on the mitochondrial membrane potential indicating a possible multi-modal mechanism of action.
Introduction:

Malaria presents a huge burden on the economic development of endemic countries (1). In 2017, WHO reported 219 million malaria cases globally, with an estimated 435,000 deaths occurring mostly amongst African children. The 20th century witnessed the development of a range of antimalarials including quinine alternatives such as mepacrine, chloroquine and primaquine, antifolates such as sulphadoxine and pyrimethamine, and artemisinin (2) (3) (4) (5) (6) (7). However, the emergence of resistance against all known classes of anti-malarial drugs including artemisinin chemotherapy, has warranted research into the development of new drugs with novel targets against the parasite (8) (9). Drug discovery is hindered by long development timelines, high attrition rates and soaring R&D costs (10).

Antimalarial chemotherapy has predominantly relied on compounds based on natural products (11). Emetine dihydrochloride hydrate, a natural product alkaloid derived from Psychotria ipecacuanha was superseded by the introduction of a safer drug metronidazole by the 1970s as an anti-amoebic drug (12). Repositioning screens carried out at the University of Salford, UK, identified emetine dihydrochloride to have potent, nanomolar in vitro anti-malarial efficacy in the multi-drug resistant K1 Plasmodium falciparum parasite strain. The comparatively significant difference in in vitro anti-protozoan efficacies (IC₅₀ 47 ± 2.1 nM in P. falciparum as compared to IC₅₀ 26.8 ± 1.27 µM in Entamoeba histolytica) dictate that the safety profile for its repositioned use as an antimalarial could be different (13) (14). The pleiotropic natural product drug has been reported to have anti-viral and anti-cancer properties, including recent reports of interrupting viral replication and cell entry for Zika and Ebola viruses (15). The 40S ribosomal subunit of the eukaryotic 80S ribosome was recently reported to be the site of action of emetine and is available as a cryo-EM
structure 3J7A (16). The definition of the target binding site for emetine enables a chimeric approach to refine using rational design, a drug discovered through repositioning.

The \((R)\) configuration at \(C-1^-\) and the presence of secondary nitrogen at position \(2^\prime\) are important for emetine's biological activity (Fig 1). Indeed, the \((S)\) configuration at \(C-1^-\) (isoemetine) or the substitution of the secondary amine results in loss of activity. Even if the asymmetry at carbons 2 and 3 are lost with unsaturation at position 2-3 (2,3-dehydroemetine) the biological activity is retained (17). In 1980, a study conducted on the cross-resistance of emetine-resistant mutants of Chinese hamster ovary cells to related compounds found that the distance between the two aromatic rings and the angle between the nucleophilic element, such as nitrogen, and the rings were essential for biological activity (18).

Emetine in its crude form has been in use since 1658 for the treatment of dysentery and was first brought to Europe from Brazil by Piso (19). Powdered ipecacuanha introduced in Mauritius in 1858 reduced the annual death rate from severe dysentery from 10-18% to 2% (20). Generalised muscle weakness, vomiting and cardiotoxicity were the side-effects with prolonged use of emetine (21) (22). A less emetic and safer synthetic analogue of emetine which could be given as a resinate 2,3-dehydroemetine, was introduced in 1959 (23). At high doses, the electrocardiographic changes were similar but were less marked and of shorter duration. The changes observed in heart conduction, contractility, automaticity and ECG abnormalities by emetine and 2,3-dehydroemetine could be due to their effect on membrane permeability to \(\text{Na}^+, \text{K}^+\) and, \(\text{Ca}^{++}\) ions. Dehydroemetine has been reported to have less cardio-toxic effects than emetine for the treatment of amoebic liver abscesses (24) (25) (26).
Previous studies have found dehydroemetine was eliminated faster from the body, and more rapidly from the heart than the liver while reverse was found to be true for emetine (27). Based on the anecdotal evidence, two diastereomers of dehydroemetine, (−)-R,S-dehydroemetine and (−)-S,S-dehydroisoemetine were synthesised. Molecular modelling tools (28) (29) were used to predict the activity of the diastereomers and their potency against the multi-drug resistant K1 strain of *P. falciparum*.

Parasites are transmitted from the mammalian hosts to mosquito vectors through mature *Plasmodium* gametocytes and hence the reinfection cycle could be broken with the use of transmission blocking antimalarials (30). Cross-resistance and gametocidal activity of emetine dihydrochloride and its synthesised analogues were tested by GSK in a bid to determine the potential of these compounds as transmission blocking drugs.

A number of studies have reported that dehydroemetine and emetine are potent inhibitors of protein synthesis (17)(31). It has also been reported that emetine affects the myocardium in a dose-dependent manner (32). Drugs inhibiting the cardiac potassium ion channel encoded by the Human ether-a-go-go related gene (hERG) can prolong the QT interval and cause a dangerous cardiac arrhythmia, *Torsades de pointes*, which has hampered a number of drug discovery and development projects (33). In this study, we tested the activity of emetine dihydrochloride and its two synthetic analogues against hERG potassium channel. The three compounds were also tested for any effect on mitochondrial membrane potential (MMP) as unpublished data from previous studies conducted by our group predicted atovaquone-like activity on MMP by the parent compound, emetine.
The preference of combinatorial regimes over monotherapy for the treatment of malaria has affected the drug discovery pipeline in a crucial way (34). Newer drug candidates have been tested for synergistic activities with existing antimalarial treatments for dose reduction to improve therapeutic and safety profiles. Furthermore, combinatorial regimes expand the shelf-life of the antimalaria drugs by delaying the emergence of resistance (35) (36).

Chou and Talalay developed a method based on the argument that the issue of synergy is more physiochemical rather than statistical in nature and employed the mass-action law principle to derive a median-effect equation where additivity could be defined using the resulting combination index (CI = 1) with antagonism and synergism defined as >1 and <1 respectively. CalcuSyn software based on the complex algorithms for median-effect analysis allows automation and eliminates subjectivity during data analysis (37). We have previously demonstrated the use of CalcuSyn as a reliable method to define antimalarial drug interactivity for combinatorial regimes (38).

Hence, to reduce dose-dependent side effects, combinatorial partner drugs showing synergistic activity were sought. (-)-R,S-Dehydroemetine was taken forward for drug interaction studies as it was found to be highly potent against the K1 strain of *P. falciparum*. Atovaquone and proguanil were first evaluated to test the efficacy of the method as the two drugs are known to exhibit synergism (39). The methodology was then applied to evaluate combinatorial partner drugs for the potent anti-malarial candidate (-)-R,S-dehydroemetine.
Results:

Molecular modelling of ligand interactions with *P. falciparum* 80S ribosome:

In order to explore the structural basis of the relative inhibitory activity of (*-*)-
R,S-dehydroemetine and (*-*)-S,S-dehydroisoemetine, we predicted and compared
their molecular interaction with *P. falciparum* 80S ribosome using computational
docking. As the receptor structure, we use the recently solved cryo-EM structure of
the 80S ribosome of *P. falciparum*, determined to a resolution of 3.2 Å (16). The
electron density corresponding to the bound emetine is located in the E-site of the
ribosomal small subunit, i.e. *Pf*40S; this E-site, a binding site that pactamycin also
recognises in the bacterial 30S subunit, is at the interface between 18S rRNA helices
23, 24, 45 and the C-terminus of protein uS11.

On closer examination of the published cryo-EM structure of the complex, the
ligand structure originally modelled into the density, erroneously corresponds to the
non-natural enantiomer of emetine, (1S,2R,3S,11bR)-emetine. This modelled
structure was not the ligand employed in the associated cryo-EM experiments (16).
Therefore, we docked emetine, i.e. the (1R,2S,3R,11bS) structure, into the identified
*Pf*40S binding site using MOE-Dock [Chemical Computing Group Inc., 1010
Sherbrooke St. West, Suite #910, Montreal, QC, Canada, H3A 2R7, 2016.]. The
docked emetine geometry maps well into the electron density envelope (shown at a
contour level 0.1542e/A³ (3.50rmsd) in Fig 2a); the bound pose broadly follows the
twisted U-shape conformation of the observed electron density, with improved
alignment in comparison to the previously published non-natural emetine enantiomer
geometry (Fig 2b).
In this U-shape, an intermolecular T-shaped π-stacking interaction is observed between the two cyclic systems of emetine, i.e. benzo[a]quinolizine rings A/B/C and isoquinoline rings D/E (Fig 1, Fig 2a). The docked emetine also forges a number of comparable interactions with the Pf40S subunit as its modelled enantiomer (Fig 2b), with a key π-stacking interaction between the A/B/C rings of emetine with the purine ring of Gua973 of h23 (16). The location of the emetine secondary and tertiary amines are broadly similar (within 1 - 2 Å), allowing hydrogen bonding interactions with a backbone oxygen atom of Ura2061 (h45) and the 2'-hydroxyl group of Ura1068 (h24) respectively (Fig 2b). The tertiary amine also forms a salt bridge interaction with the carboxylate side chain of C-terminal residue Leu151 of uS11 (Fig 3b). This interaction was not highlighted in the cryo-EM study and is a consequence of modelling the natural emetine geometry into the E-site.

Subsequently, the two diastereomers of emetine, (−)-R,S-dehydroemetine and (−)-S,S-dehydroisoemetine, were docked in turn into the emetine-binding region of the Pf40S subunit. We found that the preferred docked pose of the (−)-R,S-dehydroemetine adopts the familiar U-shaped conformation, superimposing rather closely onto the bound pose of emetine (Fig 3a). The docking scores are correspondingly similar for emetine, with a London dG value of -7.2 kcal/mol, and (−)-R,S-dehydroemetine, which has a dG score of -7.3 kcal/mol. As observed for emetine, the (−)-R,S-dehydroemetine forms the π-π stacking interaction with the Gua973 pyrimidine ring and polar interactions with Ura2061, Ura1068 and Leu151 (Fig 3b).

However, (−)-S,S-dehydroisoemetine docks into the binding site with a lower dG score of -6.5 kcal/mol and does not overlay in conformation so readily with
emetine or the (-)-R,S-dehydroemetine (Fig 3a). The particular stereochemical configuration of (-)-S,S-dehydroisoemetine appears to result in its secondary amine being more distant from the E-site residues of Pf40S. Consequently, this amine N→O Ura2061 distance extends by 0.8 Å in proceeding from R to S isomer (Fig 3b). The tertiary amine interaction with Ura1068 is maintained, however, as is the interaction with the terminal carboxylate of Leu151 (Fig 3b). The π stacking interaction with Gua973 is also present, but at a slightly larger distance between planes, increased by ~0.7 Å. Fig 4 (a) and (b) shows the predicted binding site residues for (-)-R,S-dehydroemetine and (-)-S,S-dehydroisoemetine.

**Experimental determination of IC\textsubscript{50} to test activity against the K1 strain of *P. falciparum*:**

Based on the anecdotal evidence, two synthetic analogues of emetine dihydrochloride, (-)-R,S-dehydroemetine and (-)-S,S-dehydroisoemetine were synthesised. Experiments to test drug efficacy were set up and (-)-R,S-dehydroemetine was tested in two-fold serial dilutions from 12.5 nM to 200 nM. A dose response experiment was set up on synchronised ring stage cultures of the K1 strain of *P. falciparum* to be read at 72 hours. The IC\textsubscript{50} of (-)-R,S-dehydroemetine was observed to be 71.03 ± 6.1 nM (Fig 5a). (-)-S,S-dehydroisoemetine was tested in two-fold serial dilutions from 0.625 µM to 10 µM. The IC\textsubscript{50} was observed to be 2.07 ± 0.26 µM concentration (Fig 5b). The figures are derived from representative experiments performed thrice with each concentration of (-)-R,S-dehydroemetine and (-)-S,S-dehydroisoemetine tested in triplicates.
Time-course analysis for determination of speed of action of (-)-R,S-dehydroemetine and (-)-S,S-dehydroisoemetine:

Accurate determination of the parasite killing rate in response to treatment is crucial in the development of drugs against *P. falciparum* as chemotherapy remains the primary element in the control of malaria. The speed of action of compounds on the viability of parasites is difficult to measure through traditional techniques (40). It is important to identify new drugs with rapid parasite killing kinetics early in the drug development process. Besides rapid relief of symptoms, a fast-acting drug also helps to curtail the mutations causing the development of new mechanisms of drug resistance. In 2012, Tres Cantos developed a labour intensive low-throughput assay taking up to 28 days to determine *in vitro* the parasite reduction ratio (PRR) and the presence or absence of a lag phase in response to a drug (41). The method used in this study to differentiate between fast and slow acting compounds gives initial results in 4 to 7 days (42).

The IC$_{50}$ speed assay was performed for (-)-R,S-dehydroemetine and (-)-S,S-dehydroisoemetine (with concentrations of 25 nM, 50 nM, 100 nM, 200 nM and 400 nM and 0.63 µM, 1.25 µM, 2.5 µM, 5 µM and 10 µM, respectively) using unsynchronised cultures of *P. falciparum*. The ratio of 24 hour IC$_{50}$ values to 72 hour IC$_{50}$ values for (-)-R,S-dehydroemetine and (-)-S,S-dehydroisoemetine could not be determined as IC$_{50}$ could not be reached within 24 hours. Both compounds only achieved 50% inhibition at the previously defined IC$_{50}$ values after 48 hours of exposure, indicating that the isomers have delayed action against the multi-drug resistant K1 strain of *P. falciparum*. Fig 6 shows the results for the IC$_{50}$ speed assay for (-)-R,S-dehydroemetine and (-)-S,S-dehydroisoemetine respectively (error bars represent the standard error on the experiments performed twice with each...
concentration of (-)-R,S-dehydroemetine and (-)-S,S-dehydroisoemetine tested intriplicates).

Stage-specific profiling of (-)-R,S-dehydroemetine and (-)-S,S-dehydroisoemetine using synchronised cultures of *Plasmodium falciparum*:

The two isomers of 2,3-dehydroemetine were tested on synchronous cultures

(-)-R,S-dehydroemetine was tested in two fold serial dilutions from 132.81 nM to

8500 nM and (-)-S,S-dehydroisoemetine was tested in two fold serial dilutions from

3.13 µM to 200 µM) to determine the stage-specificity of the compounds by

measuring the concentration-dependent growth of schizonts and rings following

incubation with the two compounds.

It was observed that (-)-R,S-dehydroemetine and (-)-S,S-dehydroisoemetine

affect both the ring and trophozoite/schizont stages of the parasite. The isomers

were found to be more active in the late trophozoite/schizont stage which is

consistent with the proposed protein synthesis target of the parent compound. They

displayed comparatively less activity against the rings even at high concentrations.

At the highest concentration tested, the growth rate for the rings and
trophozoites/schizonts 24h after the (-)-R,S-dehydroemetine post-exposure wash

was 50.21% and 19.75%, respectively. At the highest concentration tested, the
growth rate for the rings and trophozoites/schizonts 24h after the (-)-S,S-dehydroisoemetine post-exposure wash was 70.98% and 24.67%, respectively. The

lower potency against ring stage parasites may also in part explain the lag-phase

observed during the speed assay, where the IC$_{50}$ was not reached after 24 hours of

exposure against unsynchronised cultures.
Fig 7 shows the results for stage-specificity assay for (-)-R,S-dehydroemetine and (-)-S,S-dehydroisoemetine respectively (error bars represent the standard error on the experiments performed twice with each concentration of (-)-R,S-dehydroemetine and (-)-S,S-dehydroisoemetine tested in triplicates).

**MTT assay for cell cytotoxicity against HepG2 cells:**

MTT assay for cell cytotoxicity was performed for (-)-R,S-dehydroemetine and (-)-S,S-dehydroisoemetine. Emetine and cisplatin were used as control drugs (Fig 8). The plates were read at 48 hours (43).

Emetine was tested in two-fold serial dilutions from 31.25 nM to 2000 nM with LD$_{50}$ observed to be 199.2 ± 9.3 nM. (-)-R,S-dehydroemetine was tested in two-fold serial dilution from 11.72 nM to 750 nM with LD$_{50}$ observed to be 168.07 ± 8.65 nM. (-)-S,S-dehydroisoemetine was tested in two-fold serial dilutions from 0.312 µM to 10 µM with LD$_{50}$ observed to be 1.429 ± 0.18 µM. Cisplatin was tested in two-fold serial dilutions from 0.78 µM to 25 µM and with LD$_{50}$ observed to be 10.16 ± 2.6 µM. The selectivity index, calculated as LD$_{50}$ HepG2 / IC$_{50}$ parasites (44), for (-)-R,S-dehydroemetine was 2.37 and (-)-S,S-dehydroisoemetine was observed to be equal to 0.69.

**Determination of cross-resistance through 3H-Hypoxanthine incorporation assay:**

This assay relies on the parasite incorporation of labelled 3H-Hypoxanthine that is proportional to *P. falciparum* growth. *In-vitro* cross-resistance of the compounds is measured as an IC$_{50}$ ratio between the IC$_{50}$ value for the corresponding *P. falciparum* strain versus the IC$_{50}$ value for 3D7A. Every replicate
from a multidrug-resistant (MDR) strain involved a simultaneous determination using a 3D7A replicate to avoid any artefact linked to experimental conditions. Table 1 shows the IC$_{50}$ values of emetine dihydrochloride, (-)-R,S-dehydroemetine and (-)-S,S-dehydroisoemetine in *P. falciparum* sensitive strain (3D7A) and two *P. falciparum* resistant strains (Dd2 and W2). Using 3D7A as a reference, the ratio of *in-vitro* cross-resistance of emetine dihydrochloride was found to be 1.15 for Dd2 and 0.77 for W2. The ratio of (-)-R,S-dehydroemetine in both resistant strains, Dd2 and W2, were found to be 1.21 and 1.15 respectively.

The results showed that the inhibitory potency observed for emetine dihydrochloride and (-)-R,S-dehydroemetine in both multidrug resistant strains (Dd2 and W2) is similar to the sensitive strain 3D7A. These results suggest that there is no cross-resistance with any of the MDR strains tested.

**In-vitro IC$_{50}$ against *P. falciparum* male and female activated gametes:**

This bioassay assesses the malaria transmission blocking potential of compounds on NF54 strain by estimating their ability to prevent male mature gametocytes to progress to male microgametes or/and to inhibit female gamete activation, as indicators of gametocyte functionality. The NF54 strain was selected for its increased ability to produce gametocytes under *in-vitro* conditions (45). The activation of male gametocytes into mature microgametes is evaluated by the process of exflagellation (extrusion of rapidly waving flagellum-like microgametes from the infected erythrocyte). The activation of female gametocytes is evaluated based on the specific expression of the *Pfs25* protein at the surface of the female activated gametes (46). Male *P. falciparum* gametocytes exflagellate when activated, causing the movement of the surrounding RBCs in the media. Detecting these
changes in cells position, we were able to detect activated male gametes. Female *P. falciparum* gametocytes round up when activated and the *Pfs25* protein distributes widely in the membrane of the gamete. Using a monoclonal antibody against this protein we were able to specifically detect activated female gametes. A Dual Gamete Formation assay was performed and the results are shown in Table 2.

**hERG channel inhibition assay:**

Dose-related cardiovascular side-effects observed following treatment of amoebiasis with emetine include ECG changes such as T-wave inversion, prolongation of QT interval and widening of the QRS complex and PR interval. Hypotension, tachycardia and precordial pain were also observed (25). Stoppage of treatment resulted in complete recovery of cardiovascular functions. Cardiac microscopic examination revealed a separation of muscle fibres and destruction of myocardial fibres but an absence of inflammatory cells leading to the interpretation that the myocarditis is toxic rather than inflammatory in origin. In another study on thirty two patients, pain was noted at the injection site along with ECG abnormalities, myalgia, muscle weakness and increased levels of serum creatinine phosphatase (47). In a study on guinea pigs by Schwartz and Herrero (1965), it was observed that dehydroemetine was excreted faster than emetine. It was also postulated that reduced cardiotoxicity of dehydroemetine could be due to decreased tissue affinity to the heart in comparison to emetine (25). In a resting cardiac cell, the concentration of K\(^+\) is high intracellularly, which creates a chemical gradient for K\(^+\) to diffuse out of the cells. A subunit of the rapid delayed rectifier potassium ion channel is involved in the cardiac repolarisation (48). It is encoded by the hERG gene (Human ether-a-go-go related gene). Since emetine
is known to affect the movements of Na\(^+\), K\(^+\) and Ca\(^{2+}\) ions. 2,3-dehydroemetine is also thought to affect ion permeability. HERG channel inhibition assays were therefore carried out to determine potential influences on the previously observed cardiotoxicity with emetine therapy.

**Data Analysis of hERG channel inhibition assay:**

For each replicate the hERG response is calculated using the following equation:

\[
\% \text{ hERG response} = \frac{\text{Post - compound current (nA)}}{\text{Pre - compound current (nA)}} \times 100
\]

The % hERG response was plotted against concentration for the test compound and, where concentration-dependent inhibition was observed, the data was fitted to the following equation and an IC\(_{50}\) value calculated:

\[
y = \frac{y_{\text{max}} - y_{\text{min}}}{1 + (\frac{\text{IC}_{50}}{x})^s} + y_{\text{min}}
\]

Where: \(y\) = hERG response, \(y_{\text{max}}\) = mean vehicle control response, \(x\) = concentration, \(\text{IC}_{50}\) = concentration required to inhibit current by 50% and \(s\) = Hill slope

(-)-R,S-dehydroemetine has an IC\(_{50}\) of 19.3 µM for hERG channel whereas (-)-S,S-dehydroisoemetine has an IC\(_{50}\) of 2.99 µM. The IC\(_{50}\) of quinidine which was used as a positive control is 1.99 µM (Table 3). The selectivity index was calculated as IC\(_{50}\) hERG / IC\(_{50}\) parasites. Thus, it was found that with a selectivity index (SI) of over 271, (-)-R,S-dehydroemetine is not a hERG channel inhibitor, but (-)-S,S-dehydroisoemetine is a potent inhibitor (selectivity index = 1.48).
Staining with rhodamine123 for measurement of mitochondrial membrane potential:

Changes in mitochondrial membrane potential were measured using rhodamine123 (excitation wavelength: 511 nm and emission wavelength: 534 nm), a membrane permeable cationic fluorescent dye (49), which accumulates by electrostatic attraction in the mitochondria because of its negative transmembrane potential. A change in the dye’s concentration in the mitochondria is caused by a depolarisation event and can be visualised as a shift in fluorescent intensity of rhodamine123 (50). Draq5 (excitation wavelength: 647 nm and emission wavelength: >665 nm) is a far-red fluorescent DNA dye which is cell permeable and was used to distinguish the parasites on flow-cytometry in APC-Cy7-A channel. SYBR Green was not preferred for this experiment as it emits in the same channel as rhodamine123 and would result in the overlap of emission signals. Fluorescence microscopy was used to visualise localisation of rhodamine123 within the cytoplasm of the parasites (Fig 9).

A decrease in fluorescent intensity measured in FITC-A channel indicates a loss of mitochondrial membrane potential. Atovaquone, a known mitochondrial inhibitor was used as a control. A shift in fluorescent intensity was observed after treatment with all three compounds at IC₅₀ and IC₅₀ x 10 concentrations. Emetine and (−)-R,S-dehydroemetine showed a shift in fluorescent intensity of rhodamine123 in a direction similar to atovaquone indicating a possible mitochondrial effect (Fig 10). Atovaquone produced 41.95% and 43.17% change in mean fluorescent intensity at IC₅₀ and IC₅₀ x 10 concentrations respectively, emetine produced a change of 31.12% to 35.13% at IC₅₀ and IC₅₀ x 10 concentrations respectively, in a direction similar to atovaquone and (−)-R,S-dehydroemetine produced a change of 26.76% to...
Validation of the CalcuSyn assay for drug-interaction analysis for malaria:

CalcuSyn method has been validated in our laboratory as a useful tool for antimalarial drug interaction analysis (38). To establish the robustness of the method, the known synergistic drug combination, atovaquone and proguanil, was used. Triplicate samples were analysed by SG-plate-reader after 72 hours. In accordance with published literature, CalcuSyn predicted strong synergism between the two drugs.

Following validation of the CalcuSyn software using the atovaquone-proguanil combination, the interaction between (-)-R,S-dehydroemetine-atovaquone and (-)-R,S-dehydroemetine - proguanil were studied. The doses used for each compound were based on the known ED$_{50}$ values which served as the midpoint for a two-fold, constant-ratio dose series as shown in Table 4.

CalcuSyn-based drug-interaction analysis of the atovaquone - proguanil combination:

The CalcuSyn based analysis of the drug interactivity between atovaquone and proguanil was carried out using a constant-ratio combination of 1:7000. The output included a dose-effect curve and a median-effect plot in addition to the Combination Index (CI) and an isobologram plot, to figuratively depict the compound's potency and conformity to the mass action law (Fig 11). Specifically, CI = 0.20, 0.34 and 0.57 at the ED$_{50}$, ED$_{75}$ and ED$_{90}$ levels (Table 5), respectively were obtained inferring strong synergism at ED$_{50}$ and synergism ED$_{75}$ and ED$_{90}$. Good
Correlations coefficients of the median-effect plot were reported for atovaquone \( (r = 0.99) \), proguanil \( (r = 0.89) \), and the combination \( (r = 0.93) \), inferring good conformity to the mass-action law.

**CalcuSyn-based drug-interaction analysis for \((\text{-})\text{-}\text{R,}\text{S}-\text{dehydroemetine} - \text{atovaquone combination:}\)**

The CalcuSyn based analysis of the drug interactivity between \((\text{-})\text{-}\text{R,}\text{S}-\text{dehydroemetine} and atovaquone using a constant-ratio combination of 25:1 was done (Fig 12). Specifically, CI = 0.88, 0.88 and 0.89 at the ED\(_{50}\), ED\(_{75}\) and ED\(_{90}\) levels, respectively were obtained inferring slight synergism at all measurement points (Table 5). Good correlations coefficients of the median-effect plot were reported for atovaquone \( (r = 0.94) \), \((\text{-})\text{-}\text{R,}\text{S}-\text{dehydroemetine} \( (r = 0.94) \), and the combination \( (r = 0.96) \).

**CalcuSyn-based drug-interaction analysis for \((\text{-})\text{-}\text{R,}\text{S}-\text{dehydroemetine} - \text{proguanil combination:}\)**

The CalcuSyn based analysis of the drug interactivity between \((\text{-})\text{-}\text{R,}\text{S}-\text{dehydroemetine} and proguanil using a constant-ratio combination of 140:1 was done (Fig 13). Specifically, CI = 0.67, 1.04 and 1.62 at the ED\(_{50}\), ED\(_{75}\) and ED\(_{90}\) levels, respectively were obtained implying synergism at ED\(_{50}\), near–additive effect at ED\(_{75}\) and antagonism at ED\(_{90}\) (Table 5). Good correlation coefficients of the median-effect plot were obtained for proguanil \( (r = 0.90) \), \((\text{-})\text{-}\text{R,}\text{S}-\text{dehydroemetine} \( (r = 0.86) \), and the combination \( (r = 0.95) \), suggesting good conformity to the mass-action law.

After 72 hours of incubation, the \((\text{-})\text{-}\text{R,}\text{S}-\text{dehydroemetine} and atovaquone interaction was found to show slight synergism at all inhibitory levels analysed. For
the (-)-R,S-dehydroemetine and proguanil combination the ED$_{50}$ level of inhibition was classified as synergism, the ED$_{75}$ as nearly additive and ED$_{90}$ as antagonism.

**Discussion:**

In conclusion, we report here the nanomolar antimalarial efficacy of the synthetic emetine analogue (-)-R,S-dehydroemetine in the multi-drug resistant K1 strain of *Plasmodium falciparum* (IC$_{50}$ of 71.03 ± 6.1 nM). The clinical use of emetine dihydrochloride as an anti-amoebic drug was superseded by the better tolerated synthetic analogue 2,3-dehydroemetine in the 1970s. The isomer (-)-S,S-dehydroisoemetine was found to be less potent with an IC$_{50}$ of 2.07 ± 0.26 µM. Molecular modelling suggests that this greater potency of (-)-R,S-dehydroemetine is linked to its ability to mimic more fully the interactions of emetine with the E-site of Pf40S subunit, compared to the (-)-S,S-dehydroisoemetine isomer. The improvements in the dose-dependent cardiotoxicity previously reported for 2,3-dehydroemetine in comparison to emetine dihydrochloride was linked to decreased affinity to cardiac myocytes and increased clearance from the body (27). We propose that the very significant differential in-vitro activities of emetine dihydrochloride in *Entamoeba histolytica* (IC$_{50}$ 26.8 ± 1.27 µM) and *Plasmodium falciparum* (IC$_{50}$ 47 ± 2.1 nM) (13) (14) would mean that the dose related toxicity profile for its re-positioned use will be different.

Analysis done by GSK showed that in asexual blood stages, the compounds exhibited no cross-resistance issues. Mosquito vector dynamics, the number of people with peripheral gametocytaemia in the population, and the infectiousness of circulating gametocytes to mosquitoes determines the transmission of malaria. Interrupting transmission is an important aspect of preventing malaria in endemic
areas and there has been renewed interest in compounds preventing the formation of gametocytes. \((-)-R,S\)-dehydroemetine was found to be gametocidal. It displayed activity against both male and female gametes. Thus, it also has the potential to block the transmission of malaria.

The selectivity indices calculated using MTT assays in HepG2 cell lines was similar for emetine and its analogues. It is important to note that the low selectivity index was expected given the documented anticancer properties of emetine (51). This could explain the low LD\(_{50}\) obtained on Hep G2 lines as these are rapidly multiplying cancer cell lines. The selective advantage of \((-)-R,S\)-dehydroemetine for cardiotoxic effects is linked to its faster elimination from body, hence the appropriate toxicity investigation to define this would be the use of \textit{in vivo} animal models. It is imperative to progress this work in this direction. It was also clearly established that the cardiac toxicity for \((-)-R,S\)-dehydroemetine was not effected through the hERG channel. Our observations suggest that emetine and its two synthetic analogues produces changes in the mitochondrial membrane potential at IC\(_{50}\) concentrations, indicating a possible multi-modal mechanism of action.

The failure of monotherapy has been unambiguously demonstrated in malaria, hence, the forceful insistence by the WHO for the use of artemisinin-based combination therapy (ACT) as a policy standard. In addition to more potent therapeutic efficacies, other benefits of combination regimes include decreased toxicity, favourable synergistic interactions and most significantly, the potential to impede or delay the onset of resistance. Drug interaction analysis presented here emphasises a route to further dose reduction to minimise toxicity. \((-)-R,S\)-dehydroemetine was found to exhibit synergistic activity with proguanil and display slight synergism with atovaquone.
Emetine and its analogues, constitute a pleiotropic group of natural product-derived compounds which could potentially enhance the depleted antimalarial armamentarium, should a catastrophic gap in the drug market occur as a result of the spread of resistance to frontline antimalarials. The work presented here provides strong justification for further optimisation, particularly for use in a hospital setting in cerebral malaria, where appropriate monitoring could obviate progression of the reversible cardiotoxicity previously reported. Its hepatic concentration ability could indeed have favourable consequences for the treatment of *Plasmodium vivax* infections. The history of antimalarial chemotherapy has been largely reliant on natural product-derived leads. We provide here a significant body of evidence to progress and further optimise a previously overlooked, potent and affordable natural product compound.

**Materials and Methods:**

**Culture of *Plasmodium falciparum***

RPMI 1640 media containing 25 mM HEPES and 0.3 g/L L-glutamine (Gibco, Life Technologies, UK) supplemented with sterile filtered 2.5 g Albumax (Sigma, UK), 2.5 ml hypoxanthine (Sigma, UK), 2.5 ml 40% glucose (Dextrose Anhydrous, Fisher Scientific, UK) and 0.5 ml gentamycin (Sigma, UK), were used for the culture of erythrocytic stage, strain K1, *P. falciparum* parasites (gifted by Prof John Hyde, University of Manchester, UK, original source: Thai-K1 clone), under a 5% CO₂ 5% O₂ and 90% N₂ gas mixture (BOC Limited, UK) at 37°C. All routine culture methods were consistent with those employed by (52).

O+ human blood (purchased from NHS Blood Bank, Manchester, UK) was used routinely to maintain the parasites. Continuous cultures were maintained at 5%
Since synchronous parasite development is observed in natural hosts and this synchrony is lost quite rapidly in in-vitro cultures, sorbitol was used to keep the parasites in tight synchrony. In brief, the parasitized blood pellet was re-suspended 1:10 in 5% sorbitol (prepared in distilled water and filtered using 0.22 µm porosity Millipore filter), incubated at room temperature for 5 minutes and then centrifuged at 3000 rpm for 5 minutes. The supernatant was removed and complete media was used to wash the pellet 3 times before setting up a new culture.

**Synthesis of (-)-2,3-Dehydroemetine:**

(-)-2,3-Dehydroemetine was synthesised as per the established literature (Brossi 1967, Patent No. 3,311633 [16]). The synthesis was outsourced to Chiroblock GMBH, Germany. Previously published patent literature by chemists at Hoffmann-La Roche did not include modern analytical data such as mass spectrometry or NMR. The methodology adopted for the synthesis (-)-R,S-dehydroemetine 7 used in this study followed the published patent with minor modifications as depicted in Fig 14.

The two compounds synthesised were (-)-R,S-dehydroemetine, 7, and (-)-S,S-dehydroisoemetine, 8. Briefly, the Mannich base 1 was quaternized and reacted with the imine 2 giving piperidinone 3 as an approximately 5:1 mixture of diastereomers which were not separated. Knoevenagel condensation with malononitrile led to unsaturated dinitrile 4 in 69% yield. Hydrolysis and decarboxylation, with concomitant alekene isomerization, gave 5 after methylation. Resolution with (+)-dibenzoyl-D-tartaric acid gave homochiral (-)-5. Hydrolysis and amidation with homoveratrylamine followed by Bischler–Napieralski cyclization led to dihydroisoquinoline derivative 6, also known as 2-dehydro-O-methyl psychotine. The
cyclic imine was reduced with sodium borohydride in methanol to give a 1:1 mixture of the desired 2,3-dehydroemetine 7 and 2-dehydroisoemetine dihydrobromide 8, separated by fractional crystallization. The purity of (-)-R,S-dehydroemetine obtained through this method was 85% with the balance consisting of the diastereomer, 8.

**Molecular modelling:**

In preparation for predicting the bound pose of emetine, (-)-R,S-dehydroemetine and (-)-S,S-dehydroisoemetine, the cryo-EM structure of *P. falciparum* 80S ribosome bound to emetine dihydrochloride was obtained from the Protein Data Bank (PDB code 3J7A) (16). We note that this cryo-EM structure features the enantiomer of emetine rather than emetine itself; therefore, an initial 3D structure of emetine was obtained from the OMEGA-generated conformer in the Pubchem database (53). Subsequently emetine derivatives (-)-R,S-dehydroemetine and (-)-S,S-dehydroisoemetine were constructed using the software package MOE (54). Prior to *in silico* docking, crystallographic water molecules and a magnesium ion were removed (the latter was within 13 Å of the active site and was found to unduly influence docking solutions). Hydrogens were assigned consistent with physiological pH. Docking of ligands to the Pf40S subunit was performed using MOE-Dock[Chemical Computing Group Inc., 1010 Sherbrooke St. West, Suite #910, Montreal, QC, Canada, H3A 2R7, 2016]. The binding site region was defined using the cryo-EM ligand location. Ligand placement used the Triangle Matcher protocol. Internal flexibility was permitted for ligands but not ribosome. Poses were scored via the London dG scoring function. While this docking protocol was able to reproduce well the cryo-EM pose of the emetine stereoisomer bound to the Pf40S subunit (S1 Figure, Supporting Information), please see comment later regarding this ligand's structure.
**Drug preparation:**

Emetine dihydrochloride was obtained from Sigma Aldrich, UK. The dehydroemetine analogues were synthesised as per the established literature (Scheme 1, Brossi 1967, Patent No. 3,311633 [16]). Derivatives were validated using NMR, HPLC and FTIR. The synthesis process was outsourced to Chiroblock GMBH, Germany. Drug stock solutions were prepared in DMSO in accordance with manufacturer instructions and primary stock concentration of 5 mM was aliquoted and stored at -20°C until further use. Serial dilutions of the working solution were made using complete media for the experiments.

**Experimental determination of IC\textsubscript{50} to test activity against the K1 strain of \textit{P. falciparum}:**

Refined dose ranges were selected for emetine dihydrochloride (12.5 nM – 200 nM), (-)-\textit{R,S}-dehydroemetine (12.5 nM - 200 nM), and (-)-\textit{S,S}-dehyroisoemetine (0.625 µM - 10 µM) to permit accurate IC\textsubscript{50} calculation against the K1 strain of \textit{P. falciparum}. Ring stage parasites were diluted to 0.5-1% parasitaemia, 2.5% haematocrit (in a 96 well plate format, 200 µl final well volume) and treated for 72 hours. Dose response parasitaemia was determined using the SYBR Green-based flow cytometer or plate-reader method previously optimised in the laboratory (14).

**SYBR Green staining of erythrocytic stage \textit{P. falciparum} for flow cytometry:**

Following drug efficacy experiments, 150 µl from the control and drug-treated wells on a 96 well plate were transferred to a microcentrifuge tube and samples were washed once with PBS. The supernatant was removed and samples were incubated in the dark at room temperature for 20 minutes following addition of 1 ml of 5 x SYBR
Green solution (prepared by adding 5 µl of 10,000 x SG to 10 ml PBS). After staining, the samples were centrifuged for 1 minute at 14,000 rpm and the supernatant was discarded. Samples were re-suspended in 250 µl of 0.37% formaldehyde fixation solution prepared by diluting 36.5% formaldehyde (Sigma, UK) with PBS to a final concentration of 0.37%. The samples were placed in the fridge and incubated at 4°C for 15 minutes. Subsequently, PBS was used to wash the samples 3 times and finally the samples were suspended in 1 ml PBS. Parasitaemia was determined by SYBR green fluorescence using the FITC channel of the BD FACsVerse flow cytometer system (Blue laser, excitation laser line 488 nm \( \text{EX}_{\text{max}} 494 \text{ nm/Em}_{\text{max}} 520 \text{ nM} \)) and cell size (forward scatter, FSC-A). Fifty thousand events were recorded and in three replicates for each. Fluorescent events in drug-treated samples were compared with infected and uninfected blood counterparts and gated accordingly to obtain the percentage parasitaemia.

**Time-course analysis through IC\(_{50}\) speed assay using unsynchronised cultures of *Plasmodium falciparum*:**

The assay was used to determine the speed of action of the emetine analogues. Unsynchronised cultures of K1 strain *P. falciparum* was used and parasites were grown in presence of (-)-R,S-dehydroemetine and (-)-S,S-dehydroisoemetine for three incubation periods of 24 hours, 48 hours and 72 hours. The assays were analysed by determining SYBR green fluorescence as described above in the methodology.
Stage-specific profiling of (-)-R,S-dehydroemetine and (-)-S,S-dehydroisoemetine using synchronised cultures of *Plasmodium falciparum*:

Parasite cultures with ≥ 80% trophozoites and ≥ 80% rings were obtained by synchronisation with 5% Sorbitol (42). The cultures were synchronised twice, at 0 hours and 31 hours to obtain young rings which were up to 3 hours old. To obtain early schizont stages, the culture was synchronised twice with the second synchronisation being 6 to 8 hours after the first. Each synchronous stage was incubated for 24 hours at 37 °C on a 96-well microtitre plate with a two-fold serial dilution of the drugs ranging from 1.6 to 100 fold the IC$_{50}$ of each drug. The plates were washed 4 times after the incubation in order to dilute the drug concentration by > 1000 fold. The plates were incubated for another 24 hours at 37°C following which SYBR green staining was used to read the plates as described above.

MTT assay for cell cytotoxicity against HepG2:

HepG2 cells (University of Salford stocks purchased from American Type Culture Collection (ATCC), USA), were grown in media consisting RPMI 1640, 2 mM L-Glutamine, HEPES, 10% foetal bovine serum, 1% non-essential amino acids and 1% penicillin-streptomycin. Cells were calculated on a haemocytometer to make a new cell-media solution to a concentration of 5000 cells/100 µl and 100 µl of this new cell solution was added into each well of the 96 well plate. After 24 hours incubation, 100 µl of the drug prepared in the media were added to the wells. This was repeated in triplicate and the plate was incubated for a further 48 hours (55). After the incubation period, 50 µl of MTT solution was added to each well and incubated for 3 hours. The liquid in each well was aspirated carefully and 200 µl of DMSO was added to each well and results were read on the Ascent plate reader.
Derivation of dose-response curves and IC<sub>50</sub> values:

The infected blood controls were set at 100% for normalisation and percentage parasitaemia was calculated for drug treated samples relative to the infected control. For IC<sub>50</sub>, GraphPad prism 5.0 was used to further process the data. IC<sub>50</sub> values were calculated using nonlinear regression (GraphPad prism 5.0) by using log-transformed drug concentrations plotted against the dose response. The log(inhibitor) vs. Normalised response-Variable slope option was used for IC<sub>50</sub> calculation. Emetine dihydrochloride was used as a control drug to validate the method.

Determination of cross-resistance through IC<sub>50</sub> determination in multidrug resistant <i>P. falciparum</i> strains (carried out at Tres Cantos, GSK):

The three strains used for the assay were 3D7A, Dd2 and W2 based on their resistance profiles. 3D7A is chloroquine–sensitive, Dd2 is resistant to chloroquine, mefloquine and pyrimethamine (56) and W2 is resistant to chloroquine, quinine, pyrimethamine, cycloguanil, and sulfadoxine (57) (from the Malaria Research and Reference Reagent Resource Center MR4). A culture of parasitized red blood cells (RBC) of the corresponding strain, (0.5% parasitaemia, 2% haematocrit) in RPMI-1640, 5% albumax and 5 µM hypoxanthine was exposed to 9 dilutions (3-fold serial dilutions) of the compound starting at 5 µM. 100 µl of culture volume was plated in 96-well flat bottom microtiter plates + 0.5 µl drug (stock x200 in DMSO). Plates were incubated for 24 h at 37 ºC, 5% CO<sub>2</sub>, 5% O<sub>2</sub>, 90% N<sub>2</sub>. Next, 3H-Hypoxanthine was added and plates were incubated for another 24 h period. After that, parasites were harvested on a glass fibre filter using a TOMTEC Cell harvester 96. Filters were dried and melt-on scintillator sheets were used to determine the incorporation of 3H-
Hypoxanthine. Radioactivity was measured using a microbeta counter. Data are normalized using the incorporation of the positive control, (parasitized red blood cells without drug). IC50 values were determined using Grafit 7 program (41).

**Determination of transmission blocking potential through *in vitro* inhibition of gamete activation**

Asexual cultures of *P. falciparum* NF54 strain parasites were used to seed gametocyte cultures at 0.5% parasitaemia, 4% haematocrit in 50 ml total volume under 3% O2/ 5% CO2/ 92% N2 gas. Culture medium (RPMI 25 mM HEPES, 50 mg/l hypoxanthine, 2 g/l NaHCO3 without L-glutamine + 5% human serum and 5% Albumax) was replaced daily for 14 days. At day 14, the concentration of non-purified cultures was adjusted to plate 700,000 total cells per well in each 384-well plate. The test drugs were then added in two-fold serial dilutions starting at 10 µM (10 µM – 0.00976 µM) and incubated 48 h at 37 ºC (3% O2, 5% CO2, 92% N2).

DMSO was used as the negative control and Thiostrepton as the positive control. Activation was performed with ookinete medium (Same RPMI base used for culture but supplemented with xanthurenic acid 50 µM) supplemented with the antibody anti-Pfs25-Cy3 at a final concentration of 1/2000 (from 1 mg/ml stock). Plates were analysed to detect exflagellation centres. "Triggered" cultures were then incubated (protected from light) at 26 ºC for 24 h (in a thermoregulated incubator). Then, plates were analysed to detect female activated gametes. Activation of male gametes was detected based on light changes provoked by flagella movements which caused movement of surrounding cells. A 10-frame video was taken and then analysed to determine these changes in cell position based on pixels change. Then, the script determined where exflagellation centres were located, based also on size and intensity of light changes. Activation of female gametes was based on detection of
fluorescent Cy3-Anti Pfssp25 antibody (as the primary parameter) followed by a selection of events according to their size, roundness and the intensity of the fluorescence. Both measurements were performed using automated inverted microscope Ti-E Nikon using JOBS software. Analysis of images and videos was performed with the ICY program. The IC<sub>50</sub> value was determined using Microsoft Excel and GraphPad.

**hERG Channel Inhibition (IC<sub>50</sub> Determination) assay Protocol:**

The experiment to test the potential of emetine, (-)-R,S-dehydroemetine and (-)-S,S-dehydroisoemetine to inhibit hERG channel was outsourced to Cyprotex, UK. 100 µl of a 20 mM concentration of all three compounds in DMSO was provided to Cyprotex. Compound dilutions were prepared by diluting a DMSO solution (default 10 mM) of the test compound using a factor 5 dilution scheme into DMSO, followed by dilution into extracellular buffer such that the final concentrations tested are typically 0.008, 0.04, 0.2, 1, 5, 25 µM (final DMSO concentration 0.25%). Chinese Hamster Ovary cells expressing the hERG potassium channel were dispensed into 384-well planar arrays and hERG tail-currents were measured by whole-cell voltage-clamping. Amphotericin B was used as a perforating agent is circulated underneath the PatchPlate™ to gain electrical access to the cell. The pre-compound hERG current was measured. Emetine, (-)-R,S-dehydroemetine and (-)-S,S-dehydroisoemetine in a range of concentrations were then added to the cells and a second recording of the hERG current was made. The test compound was left in contact with the cells for 300 sec before recording currents. Quinidine, an established hERG inhibitor, was included as a positive control, and vehicle control (0.25% DMSO) as the negative control. All buffers, cell suspensions and drug
compound solutions were at room temperature. The percent change in hERG current was measured and used to calculate an IC$_{50}$ value.

Each concentration was tested in 4 replicate wells on the PatchPlate™ (maximum of 24 data points). It was ensured that only acceptable cells were used to assess hERG inhibition by applying filters. The cell must maintain a seal resistance of greater than 50 MOhm and a pre-compound current of at least 0.1 nA, and ensure cell stability between pre-and post-compound measurements.

Staining with rhodamine123 for mitochondrial membrane potential disruption:

Rhodamine123 and draq5 were used to observe the effect of emetine and its two synthetic analogues on mitochondrial membrane potential. Rhodamine123 is a mitochondrial specific dye which emits in FITC channel on flow-cytometry whereas draq5 stains the DNA and emits in APC-Cy7-A channel. The two dyes were chosen to perform the experiment as there is very minimal overlap in their emission signals.

Synchronised culture of P. falciparum K1 strain at trophozoite stage was incubated with 1 ml of 200 nM Rhodamine123 for 1 hour, followed by a further incubation with 100 µl of 10 µM Draq5 for 20 mins. Smears prepared after the incubation were immediately viewed under the fluorescence microscope at 100 x magnification to visualise localisation of the dyes inside the parasite.

To test the effect of emetine and its analogue on mitochondria, synchronised cultures of P. falciparum K1 strain at trophozoite stage were incubated at 2.5% haematocrit (in a 96 well plate format, 200 µl final well volume) for 2 hours with IC$_{50}$ and IC$_{50} \times 10$ concentrations of atovaquone, emetine hydrochloride and (-)-R,S-dehydroemetine. Compounds were then washed away by centrifuging the cultures and a pellet was prepared for each drug concentration. Pellets were then incubated
with 1 ml of 200 nM rhodamine123 for 1 hour, followed by a further incubation with 100 µl of 5 µM draq5 for 20 mins. After a wash with PBS, the experiment was read with flow-cytometer on FITC channel. Loss of mitochondrial membrane potential was indicated by a decrease in fluorescent intensity.

**Drug interaction analysis for (−)-R,S-dehydroemetine:**

Primary stock solutions were prepared as mentioned above. For experimental set up the primary stock solutions were further diluted with complete medium to give final test concentrations. A dose range of 0.125–8 x the ED$_{50}$ was made by a two-fold serial dilution for atovaquone, proguanil, and (−)-R,S-dehydroemetine. For atovaquone, the doses ranged from 0.25nM to 16nM for combination with proguanil, and 0.5 nM to 32 nM for combination with (−)-R,S-dehydroemetine. For proguanil the doses ranged from 1.75 µM to 112 µM. For (−)-R,S-dehydroemetine the doses ranged from 12.5 nM to 800 nM. At each level, the compounds were co-administered for example ED$_{50}$ of atovaquone was combined with the ED$_{50}$ of (−)-R,S-dehydroemetine and 2 x ED$_{50}$ atovaquone was combined with 2 x ED$_{50}$ (−)-R,S-dehydroemetine and so forth. Parasites were treated at ring stage and incubated for 72 hours in a 96 well plate format. The SYBR Green Plate reader method was used to determine drug susceptibility. The data was analysed for the median-effect using CalcuSyn software (Biosoft) by converting triplicate data to an averaged percentage. The r values are also reported for all sets of data. The r value represents the linear correlation coefficient for the median effect plot and indicates conformity to the mass action law. The CalcuSyn software generates the CI over a range of f$_a$ levels at different growth inhibition percentages. The interpretation of CI was done in accordance with table 6 (37).
Ethics Statement:

For routine malaria culture, anonymised whole blood packs deemed unfit/outdated for clinical use were purchased from the NHS Blood Bank at Plymouth Grove, Manchester, UK. For experiments carried out in GlaxoSmithKline, Diseases of the Developing World Medicines Development Campus, Tres Cantos, Spain, the human biological samples were sourced ethically and their research use was in accord with the terms of the informed consents under an IRB/EC approved protocol.

Acknowledgement:

We would like to acknowledge the receipt of Pump Priming Award from the University of Salford, Manchester.
References:

1. Sachs J, Malaney P. 2002. The economic and social burden of malaria. Nature 415:680-685.

2. Bruce-Chwatt LJ. 1964. Changing Tides of Chemotherapy of Malaria. British medical journal 1:581-586.

3. Butler AR, Khan S, Ferguson E. 2010. A brief history of malaria chemotherapy. The journal of the Royal College of Physicians of Edinburgh 40:172-177.

4. Slater AF. 1993. Chloroquine: mechanism of drug action and resistance in Plasmodium falciparum. Pharmacology & therapeutics 57:203-235.

5. Vale N, Moreira R, Gomes P. 2009. Primaquine revisited six decades after its discovery. European journal of medicinal chemistry 44:937-953.

6. Mbugi EV, Mutayoba BM, Malisa AL, Balthazary ST, Nyambo TB, Mshinda H. 2006. Drug resistance to sulphadoxine-pyrimethamine in Plasmodium falciparum malaria in Mlimba, Tanzania. Malaria journal 5:94.

7. Miller LH, Su X. 2011. Artemisinin: discovery from the Chinese herbal garden. Cell 146:855-858.

8. Dembele L, Gupta DK, Lim MY-X, Ang X, Selva JJ, Chotivanich K, Nguon C, Dondorp AM, Bonamy GM, Diagana TT. 2018. Imidazolopiperazines (IPZ) kill both rings and dormant rings in wild type and K13 artemisinin resistant Plasmodium falciparum in vitro. Antimicrobial Agents and Chemotherapy: AAC. 02235-02217.

9. Wongsrichanalai C, Pickard AL, Wernsdorfer WH, Meshnick SR. 2002. Epidemiology of drug-resistant malaria. The Lancet. Infectious diseases 2:209-218.
10. Schuhmacher A, Gassmann O, Hinder M. 2016. Changing R&D models in research-based pharmaceutical companies. Journal of translational medicine 14:105.

11. Ginsburg H, Deharo E. 2011. A call for using natural compounds in the development of new antimalarial treatments—an introduction. Malaria journal 10:S1.

12. Knight R. 1980. The chemotherapy of amoebiasis. Journal of Antimicrobial Chemotherapy 6:577-593.

13. Bansal D, Sehgal R, Chawla Y, Mahajan RC, Malla N. 2004. In vitro activity of antiamoebic drugs against clinical isolates of Entamoeba histolytica and Entamoeba dispar. Annals of Clinical Microbiology and Antimicrobials 3:27.

14. Matthews H, Usman-Idris M, Khan F, Read M, Nirmalan N. 2013. Drug repositioning as a route to anti-malarial drug discovery: preliminary investigation of the in vitro anti-malarial efficacy of emetine dihydrochloride hydrate. Malaria journal 12.

15. Yang S, Xu M, Lee EM, Gorshkov K, Shiryaev SA, He S, Sun W, Cheng Y-S, Hu X, Tharappel AM. 2018. Emetine inhibits Zika and Ebola virus infections through two molecular mechanisms: inhibiting viral replication and decreasing viral entry. Cell discovery 4:31.

16. Wong W, Bai XC, Brown A, Fernandez IS, Hanssen E, Condron M, Tan YH, Baum J, Scheres SH. 2014. Cryo-EM structure of the Plasmodium falciparum 80S ribosome bound to the anti/protozoan drug emetine. eLife 3.

17. Grollman AP. 1966. Structural Basis for Inhibition of Protein Synthesis by Emetine and Cycloheximide Based on an Analogy between Ipecac Alkaloids and Glutarimide Antibiotics. P Natl Acad Sci USA 56:1867-&.
18. Gupta RS, Siminovitch L. 1977. Mutants of CHO cells resistant to the protein synthesis inhibitors, cryptopleurine and tylocrebrine: genetic and biochemical evidence for common site of action of emetine, cryptopleurine, tylocrebrine, and tubulosine. Biochemistry 16:3209-3214.

19. Low GC. 1914. Recent Researches on Emetine and its Value as a Therapeutic Agent in Amœbiasis and other Diseases. Proceedings of the Royal Society of Medicine 7:41-50.

20. Rogers L. 1912. The rapid cure of amoebic dysentery and hepatitis by hypodermic injections of soluble salts of emetine. British medical journal 1:1424.

21. Davis RA. 1975. Studies on emetine cardiotoxicity in guinea pigs. The Ohio State University.

22. Bindoff L, Cullen MJ. 1978. Experimental (−) emetine myopathy: Ultrastructural and morphometric observations. Journal of the neurological sciences 39:1-15.

23. Nozaki T, Bhattacharya A. 2014. Amebiasis: Biology and Pathogenesis of Entamoeba. Springer.

24. Dempsey JJ, Salem HH. 1966. An enzymatic electrocardiographic study on toxicity of dehydroemetine. British heart journal 28:505-511.

25. Yang WC, Dubick M. 1980. Mechanism of emetine cardiotoxicity. Pharmacology & therapeutics 10:15-26.

26. Scragg J, Powell S. 1968. Emetine hydrochloride and dehydroemetine combined with chloroquine in the treatment of children with amoebic liver abscess. Archives of disease in childhood 43:121.
27. Schwartz D, Herrero J. 1965. Comparative pharmacokinetic studies of dehydroemetine and emetine in guinea pigs using spectrofluorometric and radiometric methods. The American journal of tropical medicine and hygiene 14:78-83.

28. Trott O, Olson AJ. 2010. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. Journal of computational chemistry 31:455-461.

29. Rajamani R, Good AC. 2007. Ranking poses in structure-based lead discovery and optimization: current trends in scoring function development. Current opinion in drug discovery & development 10:308-315.

30. Delves MJ, Ruecker A, Straschil U, Lelièvre J, Marques S, López-Barragán MJ, Herreros E, Sinden RE. 2013. Male and female Plasmodium falciparum mature gametocytes show different responses to antimalarial drugs. Antimicrobial agents and chemotherapy 57:3268-3274.

31. Perlman S, Penman S. 1970. Mitochondrial protein synthesis: resistance to emetine and response to RNA synthesis inhibitors. Biochemical and biophysical research communications 40:941-948.

32. Watkins WD, Guess WL. 1968. Toxicity of emetine to isolated embryonic chick-heart cells. Journal of pharmaceutical sciences 57:1968-1974.

33. Nachimuthu S, Assar MD, Schussler JM. 2012. Drug-induced QT interval prolongation: mechanisms and clinical management. Therapeutic advances in drug safety 3:241-253.

34. Bell A. 2005. Antimalarial drug synergism and antagonism: mechanistic and clinical significance. FEMS microbiology letters 253:171-184.
35. Kremsner PG, Krishna S. 2004. Antimalarial combinations. The Lancet 364:285-294.

36. Harasym TO, Liboiron BD, Mayer LD. 2010. Drug ratio-dependent antagonism: a new category of multidrug resistance and strategies for its circumvention. Multi-Drug Resistance in Cancer:291-323.

37. Chou T-C. 2010. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer research 70:440-446.

38. Matthews H, Deakin J, Rajab M, Idris-Usman M, Nirmalan NJ. 2017. Investigating antimalarial drug interactions of emetine dihydrochloride hydrate using CalcuSyn-based interactivity calculations. PloS one 12:e0173303.

39. Radloff PD, Philips J, Nkeyi M, Kremsner P, Hutchinson D. 1996. Atovaquone and proguanil for Plasmodium falciparum malaria. The Lancet 347:1511-1514.

40. Burrows JN, Leroy D, Lotharius J, Waterson D. 2011. Challenges in antimalarial drug discovery. Future Med Chem 3:1401-1412.

41. Sanz LM, Crespo B, De-Cózar C, Ding XC, Llergo JL, Burrows JN, García-Bustos JF, Gamo F-J. 2012. P. falciparum in vitro killing rates allow to discriminate between different antimalarial mode-of-action. PloS one 7:e30949.

42. Le Manach C, Scheurer C, Sax S, Schleiferböck S, Cabrera DG, Younis Y, Paquet T, Street L, Smith P, Ding XC. 2013. Fast in vitro methods to determine the speed of action and the stage-specificity of anti-malarials in Plasmodium falciparum. Malaria journal 12:424.

43. de Sena Correia VC, Lima NO, de Souza Oliveira FA, dos Santos APdA, Teles CBG, de Oliveira Júnior WP, Pimenta RS. 2016. Evaluation of the
antiplasmodial and leishmanicidal potential of Myrciaria dubia (Myrtaceae) extract. Revista da Sociedade Brasileira de Medicina Tropical 49:586.

44. Kaiser M, Mäser P, Tadoori LP, Ioset J-R, Brun R. 2015. Antiprotozoal activity profiling of approved drugs: a starting point toward drug repositioning. PloS one 10:e0135556.

45. Bryant JM, Baumgarten S, Lorthiois A, Scheidig-Benatar C, Claës A, Scherf A. 2018. De Novo Genome Assembly of a Plasmodium falciparum NF54 Clone Using Single-Molecule Real-Time Sequencing. Genome Announc. 6:e01479-01417.

46. Miguel-Blanco C, Lelièvre J, Delves MJ, Bardera AI, Presa JL, López-Barragán MJ, Ruecker A, Marques S, Sinden RE, Herreros E. 2015. Imaging-based high-throughput screening assay to identify new molecules with transmission-blocking potential against Plasmodium falciparum female gamete formation. Antimicrobial agents and chemotherapy 59:3298-3305.

47. Mastrangelo MJ, Grage TB, Bellet RE, Weiss AJ. 1973. A phase I study of emetine hydrochloride (NSC 33669) in solid tumors. Cancer 31:1170-1175.

48. Sanguinetti MC, Tristani-Firouzi M. 2006. hERG potassium channels and cardiac arrhythmia. Nature 440:463-469.

49. Tanabe K. 1990. Glucose transport in malaria infected erythrocytes. Parasitology today 6:225-229.

50. Gaur R, Pathania AS, Malik FA, Bhakuni RS, Verma RK. 2016. Synthesis of a series of novel dihydroartemisinin monomers and dimers containing chalcone as a linker and their anticancer activity. European journal of medicinal chemistry 122:232-246.
51. Uzor PF. 2016. Recent developments on potential new applications of emetine as anti-cancer agent. EXCLI journal 15:323.

52. Read M, Hyde JE. 1993. Simple in vitro cultivation of the malaria parasite *Plasmodium falciparum* (erythrocytic stages) suitable for large-scale preparations. Methods in molecular biology 21:43-55.

53. Omega V. 2006. 2.1, OpenEye Scientific Software. Inc.: Santa Fe, NM.

54. Molecular Operating Environment (MOE), 2015.10; Chemical Computing Group Inc., 1010 Sherbrooke St. West, Suite #910, Montreal, QC, Canada, H3A 2R7, 2016.

55. Vale VV, Vilhena TC, Trindade RCS, Ferreira MRC, Percário S, Soares LF, Pereira WLA, Brandão GC, Oliveira AB, Dolabela MF. 2015. Anti-malarial activity and toxicity assessment of Himatanthus articulatus, a plant used to treat malaria in the Brazilian Amazon. Malaria journal 14:132.

56. Sun W, Tanaka TQ, Magle CT, Huang W, Southall N, Huang R, Dehdashti SJ, McKew JC, Williamson KC, Zheng W. 2014. Chemical signatures and new drug targets for gametocytocidal drug development. Scientific reports 4:3743.

57. Rathod PK, McErlean T, Lee P-C. 1997. Variations in frequencies of drug resistance in *Plasmodium falciparum*. Proceedings of the National Academy of Sciences 94:9389-9393.
Figures:

Figure 1

Fig 1: Structure of emetine hydrochloride.
Fig 2 (a) Overlay of the docked pose of emetine (green) with its enantiomer present in the cryo-EM structure (maroon); observed electron density envelope is also shown (wireframe surface with contour level 0.1542e/A$^3$ (3.50rmsd)); (b) Interactions of docked emetine (green) with Pf40S residues and comparison with previously modelled interactions of its enantiomer (blue) (16).
Figure 3  (a) Overlay of docked poses of (-)-R,S-dehydroemetine (red) and (-)-S,S-dehydroisoemetine (cyan) with emetine (blue). (b) Interactions of (-)-R,S-dehydroemetine (red) and (-)-S,S-dehydroisoemetine (cyan) with the Pf40S binding site. Distances (dotted lines) in Å.
**Figure 4**

(a) Docking through MOE showing the binding site residues for (-)-R,S-dehydroemetine molecule. (b) Docking through MOE showing the binding site residues for (-)-S,S-dehydroisoemetine molecule.
Figure 5

(a) The effective dose of (-)-R,S-dehydroemetine (dose range tested in two-fold serial dilutions from 12.5 nM to 200 nM) on *P. falciparum* (K1) infection after an incubation period of 72 hours using SYBR Green-based plate-reader assay. (b) The effective dose of (-)-S,S-dehydroisoemetine (dose range tested in two-fold serial dilutions from 0.625 µM to 10 µM) on *P. falciparum* (K1) infection after an incubation period of 72 hours using SYBR Green-based plate-reader assay. The experiments were performed thrice with each concentration of (-)-R,S-dehydroemetine and (-)-S,S-dehydroisoemetine tested in triplicates. Data were analysed using GraphPad prism.
Figure 6: Time-course analysis through IC₅₀ speed assay using unsynchronised cultures of *Plasmodium falciparum*:

The graphs show that IC₅₀ values could not be reached within 24 hours. (-)R,S-dehydroemetine and (-)S,S-dehydroisoemetine reached the IC₅₀ by 48 hours. Error bars represent the standard error on the experiments performed twice with each concentration of (-)R,S-dehydroemetine and (-)S,S-dehydroisoemetine tested in triplicates (a) (-)R,S-dehydroemetine with concentration (25, 50, 100, 200 and 400 nM) at 24h, 48h and 72h, (b) (-)S,S-dehydroisoemetine with concentration (0.63, 1.25, 2.5, 5 and 10 µM) at 24h, 48h and 72h.
Fig 7: Stage-specific profiling using synchronised cultures of *Plasmodium falciparum*.

The decrease in growth of trophozoites/schizonts was observed to be more marked in comparison to rings. The drug effects are expressed as a percentage of growth of the rings relative to trophozoites/schizonts 24h after the post-exposure wash. Error bars represent the standard error on the experiments performed twice with each concentration of (-)-R,S-dehydroemetine and (-)-S,S-dehydroisoemetine tested in triplicates. (a) Cultures were exposed to a serial dilution of (-)-R,S-dehydroemetine (from 132.81 nM to 8500 nM) for 24h, (b) Cultures were exposed to a serial dilution of (-)-S,S-dehydroisoemetine (from 3.13 µM to 200 µM) for 24h.
Figure 8

Fig 8: 48 hour MTT assay

Cells were seeded at 5000 cells per well. Cell viability was determined using a standard MTT assay. Data was analysed using GraphPad prism. Error bars represent the standard deviation on the experiments performed thrice with each concentration of emetine, cisplatin, (-)-R,S-dehydroemetine and (-)-S,S-dehydroisoemetine tested in triplicate. (a) 48 hour MTT assay for emetine, tested in two-fold serial dilutions from 31.25 nM to 2000 nM, (b) 48 hour MTT assay for cisplatin, tested in two-fold serial dilutions from 0.78 µM to 25 µM, (c) 48 hour MTT assay for (-)-R,S-dehydroemetine, tested in two-fold serial dilutions from 11.72 nM to
750 nM, and (d) 48 hour MTT assay for (-)-S,S-dehydroisoemetine, tested in two-fold serial dilutions from 0.312 μM to 10 μM.

Figure 9

Fig 9: Staining of parasites with rhodamine123 and draq5.

The parasites were stained with rhodamine123 and draq5. Merge with brightfield shows localisation of the dye within the parasite. *P. falciparum* K1 strain trophozoites stained with (A) Draq5 10 μM, (B) Rhodamine123 200 nM, (C) Draq5 and
Rhodamine merge and (D) Draq5, rhodamine123 and brightfield merge. Visualised under fluorescence microscope at 100x magnification.

**Figure 10**

![Graphical representation of change in fluorescent intensity on application of drugs at IC<sub>50</sub> concentration](image)

![Table showing changes in fluorescent intensity (FITC-A mean) on application of drugs at IC<sub>50</sub> and IC<sub>50</sub> x 10 concentrations](image)

**Fig 10: Disruption of mitochondrial membrane potential**

Changes in mitochondrial membrane potential observed on treatment with IC<sub>50</sub> of atovaquone, emetine and (-)-R,S-dehydroemetine. (a) Graphical representation of change in fluorescent intensity on application of drugs at IC<sub>50</sub> concentration, (b) Table showing changes in fluorescent intensity (FITC-A mean) on application of drugs at IC<sub>50</sub> and IC<sub>50</sub> x 10 concentrations. FITC-A mean of infected blood without drugs was considered to be the base value (0) and FITC-A mean of the compounds are represented as percentage deviation from the base value.
Fig 11: CalcuSyn-based drug interactivity analysis for atovaquone and proguanil. (a) CalcuSyn based median effect plot, (b) isobologram, and (c) dose-effect curve analysed through GraphPad Prism for drug interactivity between atovaquone and proguanil. Atovaquone and proguanil (1:7000) combination was found to be strongly synergistic at IC₅₀ (CI = 0.21) and IC₇₅ (CI = 0.34), and synergistic at IC₉₀ (CI = 0.57)
Fig 12: CalcuSyn-based drug interactivity analysis for (-)-R,S-dehydroemetine - atovaquone combination.

Dose-effect curve analysed through GraphPad Prism for drug interactivity between (-)-R,S-dehydroemetine and atovaquone. Atovaquone and (-)-R,S-dehydroemetine (1:25) combination was found to display slight synergy at IC50 (CI = 0.88), IC75 (CI = 0.88) and IC90 (CI = 0.89).
Fig 13: CalcuSyn drug interactivity analysis for proguanil and (-)-R,S-dehydroemetine combination.

Dose-effect curve analysed through GraphPad Prism for drug interactivity between proguanil and (-)-R,S-dehydroemetine. Proguanil and (-)-R,S-Dehydroemetine (140:1) combination was found to be synergistic at IC_{50} (CI = 0.67), nearly additive at IC_{75} (CI = 1.04) and antagonistic at IC_{90} (CI = 1.62).
**Figure 14** Synthesis of 2, 3-dehydroemetine.

**Conditions:**

a) i. iodomethane, ethanol, rt, 24 h, ii. 2, KOAc, reflux, 3 h, 72%;

b) malononitrile, ammonium acetate/acetic acid, toluene, reflux, 2.5 h, 69%;

c) i. 20% HCl, reflux, 5 h, ii. methanolic HCl, rt, 18 h, 45%;

d. (+)-dibenzoyl tartrate, methanol, two recrystallizations, 25%;

e) i. 3M HCl, reflux, 90 min, ii. 3,4-dimethoxyphenethylamine, xylenes, reflux, 18 h, iii. POCl₃, benzene, reflux, 1 h, 28%;

f) NaBH₄, methanol, rt, 1 h, 81% of a 1:1 diastereomeric mixture.

7: (S)-2-((R)-6,7-Dimethoxy-1,2,3,4-tetrahydro-isoquinolin-1-ylmethyl)-3-ethyl-9,10-dimethoxy-1,6,7,11b-tetrahydro-4H-pyrido[2,1-a]isoquinoline * dihydrobromide
8: (S)-2-((S)-6,7-Dimethoxy-1,2,3,4-tetrahydro-isoquinolin-1-ylmethyl)-3-ethyl-9,10-dimethoxy-1,6,7,11b-tetrahydro-4H-pyrido[2,1-a]isoquinoline \* dihydrobromide

**Tables:**

**Table 1: Analysis of results to determine cross-resistance through 3H-Hypoxanthine incorporation assay**

| Compounds                     | 3D7A IC<sub>50</sub> (µM) | SD | Dd2 IC<sub>50</sub> (µM) | SD | W2 IC<sub>50</sub> (µM) | SD | ratio Dd2/3D7A | ratio W2/3D7A |
|-------------------------------|---------------------------|----|--------------------------|----|-------------------------|----|----------------|----------------|
| Emetine dihydrochloride       | 0.234                     | 0.022 | 0.269                    | 0.025 | 0.181                   | 0   | 1.15           | 0.77           |
| (-)-<i>R</i>,<i>S</i>-dehydroemetine | 0.146                     | 0.003 | 0.177                    | 0.014 | 0.168                   | 0.005 | 1.21           | 1.15           |
| (-)-<i>S</i>,<i>S</i>-dehydroisoemetine | 1.031                     | 0.041 | ND                       | ND | ND                      | ND |                 |                |

*In-vitro* IC<sub>50</sub> values of emetine dihydrochloride, (-)-<i>R</i>,<i>S</i>-dehydroemetine and (-)-<i>S</i>,<i>S</i>-dehydroisoemetine in *P. falciparum* sensitive strain (3D7A) and *P. falciparum* resistant strains (Dd2 and W2). It also shows the ratios of *in-vitro* cross-resistance of emetine dihydrochloride and (-)-<i>R</i>,<i>S</i>-dehydroemetine in both resistant strains (Dd2 and W2) using 3D7A strain as reference (SD denotes standard deviation).
Table 2: \textit{In-vitro} IC\textsubscript{50} values of (−)-R,S-dehydroemetine and (−)-S,S-dehydroisoemetine against male and female gametocytes in \textit{P. falciparum} NF54 strain

| Compounds                          | \textit{P. falciparum} Dual Gamete Formation Assay |
|------------------------------------|----------------------------------------------------|
|                                    | Male | Female |
|                                    | Average | SD | Average | SD |
| (−)-R,S-dehydroemetine (µM)        | 0.43  | 0.02 | 1.04    | 0.02 |
| (−)-S,S-dehydroisoemetine (µM)     | >10   | >10   |          |      |

\textit{In-vitro} IC\textsubscript{50} values of (−)-R,S-dehydroemetine and (−)-S,S-dehydroisoemetine against male and female gametocytes in \textit{P. falciparum} NF54 strain.

Table 3: hERG channel inhibition assay results for (−)-R,S-dehydroemetine and (−)-S,S-dehydroisoemetine

| Cyprotex                  | hERG channel inhibition (IC\textsubscript{50} determination) |
|---------------------------|---------------------------------------------------------------|
|                           | % Mean inhibition                                             |
| Compounds                 | 0 µM | 0.016 µM | 0.08 µM | 0.4 µM | 2 µM | 10 µM | 50 µM | IC\textsubscript{50} (µM) |
| (−)-R,S-dehydroemetine    | 7.79 | 6.34     | 12.7    | 7.21   | 39.4 | 61.4  | 19.3  |
| (−)-S,S-dehydroisoemetine| 8.13 | 4.61     | 9.33    | 36     | 70.7 | 96.9  | 2.99  |

Effect of (−)-R,S-dehydroemetine and (−)-S,S-dehydroisoemetine determined using hERG channel inhibition assay. Each value is a mean of triplicate values.
Table 4: The dose series used for the combination of existing antimalarials (AM) with (-)-R,S-dehydroemetine

| Level | (-)-R,S-dehydroemetine (nM) | Atovaquone (nM) | Proguanil (µM) |
|-------|-------------------------------|-----------------|----------------|
| A     | 12.5                          | 0.5             | 1.75           |
| B     | 25                            | 1               | 3.5            |
| C     | 50                            | 2               | 7              |
| D     | 100                           | 4               | 14             |
| E     | 200                           | 8               | 28             |
| F     | 400                           | 16              | 56             |
| G     | 800                           | 32              | 112            |

Combination ratio with (-)-R,S-dehydroemetine

Table 5: CalcuSyn-based drug interaction analysis

| Drug interaction                    | Combination Index values (CI) | r  |
|-------------------------------------|-------------------------------|----|
|                                     | ED$_{50}$ | ED$_{75}$ | ED$_{90}$ |
| Atovaquone and Proguanil (1:7000)  | 0.21      | 0.34      | 0.57      | 0.93  |
| Atovaquone and (-)-R,S-dehydroemetine (1:25) | 0.88      | 0.88      | 0.89      | 0.96  |
| Proguanil and (-)-R,S-dehydroemetine (140:1) | 0.67      | 1.04      | 1.62      | 0.95  |

The combination ratios and CalcuSyn determined Combination Index (CI) values for the assays performed. The r value represents the linear correlation coefficient for the median effect plot and indicates conformity to the mass action law.
Table 6: Classification of synergism or antagonism using CI values generated by Chou-Talalay method (Source: CalcuSyn manual, Biosoft, 2006)

| Range of CI  | Symbol | Description            |
|-------------|--------|------------------------|
| <0.1        | +++++  | Very strong synergism  |
| 0.1-0.3     | +++++  | Strong synergism       |
| 0.3-0.7     | +++    | Synergism              |
| 0.7-0.85    | ++     | Moderate synergism     |
| 0.85-0.90   | +      | Slight synergism       |
| 0.90-1.10   | ±       | Nearly additive        |
| 1.10-1.20   | -      | Slight antagonism      |
| 1.20-1.45   | --     | Moderate antagonism    |
| 1.45-3.3    | ---    | Antagonism             |
| 3.3-10      | ----   | Strong antagonism      |
| >10         | ------ | Very strong antagonism |